Literature DB >> 15012889

[Prognostic and predictive factors of patients with cancer of unknown origin treated with a paclitaxel-based chemotherapy].

Alberto Muñoz1, Natalia Fuente, Ramón Barceló, Itziar Rubio, Josefa Ferreiro, Guillermo López Vivanco.   

Abstract

BACKGROUND AND
OBJECTIVE: Taxane-based combinations appear to be promising for the treatment of carcinoma of unknown primary site (CUPS). PATIENTS AND
METHOD: Patients with CUPS not corresponding to any favourable subset were treated with paclitaxel, carboplatin and etoposide. Interaction between various factors with survival was analyzed. A regression model was applied to identify factors with independent prognostic significance.
RESULTS: 48 patients were included and 15 responses were observed with a median overall survival of 7.4 months. In the multivariate analysis, performance status and hypoalbuminemia were negatively associated with overall survival.
CONCLUSIONS: Some patients can achieve complete response and prolonged survival. This treatment cannot be recommended for patients with a regular performance status. A better knowledge of prognostic factors and a definition of more subgroups with favourable outcome are needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012889     DOI: 10.1016/s0025-7753(04)74200-1

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  2 in total

1.  Prognostic factors in cancer of unknown primary site.

Authors:  A Muñoz; N Fuente; I Rubio; J Ferreiro; A Martínez-Bueno; G López-Vivanco
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

2.  [Palliative chemotherapy and CUP-syndrome: medical intentions versus patients' attitudes in decision making].

Authors:  Stephan Iglseder
Journal:  Wien Med Wochenschr       Date:  2006-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.